Rubicon Research Private recalls

Rubicon Research Private has 4 recalls on record with the FDA and USDA, the earliest in 2022 and the latest reported on 25 Sep 2024. 3 are still ongoing.

Total recalls4since 2022

Last 12 months0reported

Class I00% of total

Ongoing3latest 25 Sep 2024

Recalls per month, last 24 months

click a bar for that month

0Oct '24 0 0 0Jan '25 0 0 0Apr 0 0 0Jul 0 0 0Oct 0 0 0Jan '26 0 0 0Apr 0 0 0Jul 0 0

Severity split

Class I 0 0%Class II 3 75%Class III 1 25%

Why rubicon research private is recalled

Other Reasons250%
Foreign Material250%

Product types

Blood Pressure Medication250%
Pain Medication125%

Brands

By year

2024375%
2022125%

Ongoing rubicon research private recalls

3 active

Reported	Class	Recall	Company	Reason	Where
25 Sep 2024Drug	CLASS III	AcetaZOLAMIDE Tablets, USP, 125 mg bottled recalledAcetazolamide	Rubicon Research Private	Other	Nationwide
5 Jun 2024Drug	CLASS II	Metoprolol Tartrate Tablets USP, 25mg recalledMetoprolol Tartrate	Rubicon Research Private	Foreign Material	Nationwide
15 May 2024Drug	CLASS II	traMADol Hydrochloride Tablets, USP 50 mg recalledTramadol Hydrochloride	Rubicon Research Private	Other	Nationwide

All rubicon research private recalls, newest first

4 total

Reported	Class	Recall	Company	Reason	Where
25 Sep 2024Drug	CLASS III	AcetaZOLAMIDE Tablets, USP, 125 mg bottled recalledAcetazolamide	Rubicon Research Private	Other	Nationwide
5 Jun 2024Drug	CLASS II	Metoprolol Tartrate Tablets USP, 25mg recalledMetoprolol Tartrate	Rubicon Research Private	Foreign Material	Nationwide
15 May 2024Drug	CLASS II	traMADol Hydrochloride Tablets, USP 50 mg recalledTramadol Hydrochloride	Rubicon Research Private	Other	Nationwide
19 Jan 2022Drug	CLASS II	Metoprolol Tartrate Tablets, USP 25 mg recalledMetoprolol Tartrate	Rubicon Research Private	Foreign Material	Nationwide

About this list

Records come from FDA enforcement reports and USDA FSIS notices, grouped by normalised name. A company operating under several names may appear more than once.